| Literature DB >> 34820172 |
Yan Zhu1,2, Jinlan Rao1, Jingsi Wei1, Liu Liu1, Shanshan Huang1, Jingjing Lan1, Chao Xue1, Wei Li1.
Abstract
BACKGROUND: Microscopic polyangiitis (MPA) is a systemic autoimmune disease characterized by inflammation of small- and medium-sized blood vessels. Autophagy-related protein polymorphisms are involved in autoimmune disease. The aim of this study was to evaluate the effects of single-nucleotide polymorphisms (SNPs) in the ULK1 and PIK3CA genes on the risk of MPA.Entities:
Keywords: Gene polymorphism; Microscopic polyangiitis; PIK3CA; ULK1
Year: 2021 PMID: 34820172 PMCID: PMC8588863 DOI: 10.7717/peerj.12377
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Demographic characteristic of the study participants.
| Characteristic | MPA group ( | Control group ( |
|---|---|---|
| Age (years) | 54.6 ± 14.9 | 51.2 ± 12.6 |
| <60 | 114 (54.8) | 160 (75.8) |
| ≥60 | 94 (45.2) | 51 (24.2) |
| Sex (M/F) | 78/130 | 83/128 |
| Ethnicity (Han/Zhuang) | 131/75 | 155/56 |
| BVAS (mean ± SD) | 16.8 ± 4.43 | – |
| Renal pathologic classification (Renal biopsy, | ||
| Focal | 36 (40.4%) | |
| Crescentic | 9 (10.1%) | |
| Mixed | 20 (22.5%) | |
| Sclerotic | 24 (27.0%) | |
| Renal tubulointerstitial injury (Renal biopsy, | ||
| Score 1 | 37 (41.6%) | |
| Score 2 | 41 (46.1%) | |
| Score 3 | 11 (12.4%) |
Basic information about SNPs in ULK1 and PIK3CA and their association with the risk of MPA.
| Gene | SNP ID | Location | Alleles | MAF | |||
|---|---|---|---|---|---|---|---|
| Case | Control | ||||||
|
|
| 12:132378133 | G>C | 0.079 | 0.069 | 0.571 | 0.832 |
|
| 12:132399065 | T>G | 0.200 | 0.185 | 0.566 | 0.678 | |
|
| 12:132400309 | A>G | 0.406 | 0.356 | 0.143 |
| |
|
| 12:132405421 | C>T | 0.099 | 0.090 | 0.673 | 0.897 | |
|
| 12:132406666 | G>C | 0.174 | 0.167 | 0.781 | 0.853 | |
|
| 12:132407089 | A>G | 0.442 | 0.378 | 0.060 | 0.070 | |
|
|
| 3:178950297 | C>T | 0.240 | 0.325 |
|
|
|
| 3:178952507 | G>T | 0.168 | 0.165 | 0.901 | 0.765 | |
The genotype frequencies of the studied ULK1 and PIK3CA gene SNPs in the cases and the healthy controls.
| SNP ID | Model | Genotype | Control | Case | OR (95% CI) |
|
|---|---|---|---|---|---|---|
| Codominant | AA | 92 (44) | 67 (32.4) | 1.00 |
| |
| Dominant | AA | 92 (44) | 68 (31.9) | 1.00 |
| |
| Recessive | AA+GA | 177 (84.7) | 184 (86.4) | 1.00 | 0.61 | |
| Overdominant | AA+GG | 124 (59.3) | 97 (45.5) | 1.00 |
| |
| Codominant | AA | 81 (38.8) | 73 (34.3) | 1.00 | 0.086 | |
| Dominant | AA | 81 (38.8) | 73 (34.3) | 1.00 | 0.36 | |
| Recessive | AA/AG | 179 (85.7) | 163 (76.5) | 1.00 |
| |
| Overdominant | AA/GG | 111 (53.1) | 123 (57.8) | 1.00 | 0.34 | |
| Codominant | CC | 101 (48.6) | 138 (64.3) | 1.00 |
| |
| Dominant | CC | 101 (48.6) | 128 (64.3) | 1.00 |
| |
| Recessive | CC/CT | 180 (86.5) | 173 (86.9) | 1.00 | 0.97 | |
| Overdominant | CC/TT | 129 (62) | 154 (77.4) | 1.00 |
|
Figure 1Graphical representation of the SNP locations and LD structure.
(A) LD plots containing 6 SNPs from ULK1; (B) LD plots containing 2 SNPs from PIK3CA.
The correlation between the haplotypes of ULK1 and PIK3CA gene SNPs and the MPA susceptibility.
| Gene | Haplotype | Case ( | Control ( | OR (95% CI) |
|
|---|---|---|---|---|---|
|
| C-T-A-C-C-G | 27.6 (6.7%) | 27.1(6.5%) | 1.039 (0.599∼1.799) | 0.893 |
| G-G-G-G-G | 80.8 (19.5%) | 67.0(16%) | 1.285 (0.897∼1.841) | 0.171 | |
| G-T-A-C-G-A | 203.7 (49.2%) | 234.5(56.1%) |
|
| |
| G-T-G-C-G-A | 13.9 (3.4%) | 10.6 (2.5%) | 1.343 (0.596∼3.024) | 0.475 | |
| G-T-G-C-G-G | 26.8 (6.5%) | 20.7 (4.9%) | 1.340 (0.741∼2.422) | 0.331 | |
| G-T-G-T-C-G | 30.8 (7.4%) | 29.9 (7.1%) | 1.054 (0.624∼1.780) | 0.844 | |
|
| C-G | 291.5 (73.3%) | 278.7(66.7%) |
|
|
| T-G | 36.5 (8.8%) | 68.3 (16.3%) |
|
| |
| T-T | 62.5 (15.7%) | 66.7 (16.0%) | 0.993 (0.681∼1.446] | 0.9688 |
Distribution of ULK1 and PIK3CA polymorphisms in population of different ages and its association with the risk of MPA.
| SNP ID | Model | Geno | Age <60 years | Age ≥ 60 years | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control | Case | OR (95% CI) | Control | Case | OR (95% CI) | |||||
| Codominant | AA | 72 (45%) | 39 (34.2%) | 1.00 | 20 (40.8%) | 28 (30.1%) | 1.00 | |||
| GA | 62 (38.8%) | 58 (50.9%) | 1.74 (1.02–2.96) | 0.12 | 23 (46.9%) | 54 (58.1%) | 1.66 (0.78–3.53) | 0.42 | ||
| GG | 26 (16.2%) | 17 (14.9%) | 1.21 (0.59–2.49) | 6 (12.2%) | 11 (11.8%) | 1.37 (0.43–4.35) | ||||
| Dominant | AA | 72 (45%) | 39 (34.2%) | 1.00 | 20 (40.8%) | 28 (20.1%) | 1.00 | |||
| GA/GG | 88 (55%) | 75 (65.8%) | 1.58 (0.96–2.60) | 0.073 | 29 (59.2%) | 65 (69.9%) | 1.60 (0.77–3.30) | 0.21 | ||
| Recessive | AA/GA | 134 (83.8%) | 97 (85.1%) | 1.00 | 43 (87.8%) | 82 (88.2%) | 1.00 | |||
| GG | 26 (16.2%) | 17 (14.9%) | 0.90 (0.47–1.76) | 0.77 | 6 (12.2%) | 11 (11.8%) | 1.01 (0.35–2.95) | 0.98 | ||
| Overdominant | AA/GG | 98 (61.2%) | 56 (49.1%) | 1.00 | 26 (53.1%) | 39 (41.9%) | 1.00 | |||
| GA | 62 (38.8%) | 58 (50.9%) |
|
| 23 (46.9%) | 54 (58.1%) | 1.53 (0.76–3.08) | 0.23 | ||
| Codominant | AA | 63 (39.4%) | 40 (35.1%) | 1.00 | 18 (36.7%) | 32 (34.4%) | 1.00 | |||
| AG | 74 (46.2%) | 47 (41.2%) | 0.99 (0.57–1.70) | 0.14 | 24 (49%) | 40 (43%) | 0.92 (0.42–1.99) | 0.44 | ||
| GG | 23 (14.4%) | 27 (23.7%) | 1.87(0.94–3.71) | 7 (14.3%) | 21 (22.6%) | 1.73 (0.61–4.88) | ||||
| Dominant | AA | 63 (39.4%) | 40 (35.1%) | 1.00 | 18 (36.7%) | 32 (34.4%) | 1.00 | |||
| AG/GG | 97 (60.6%) | 74 (64.9%) | 1.20 (0.73–1.98) | 0.47 | 31 (63.3%) | 61 (65.6%) | 1.10 (0.53–2.27) | 0.8 | ||
| Recessive | AA/AG | 137 (85.6%) | 87 (76.3%) | 1.00 | 42 (85.7%) | 72 (77.4%) | 1.00 | |||
| GG | 23 (14.4%) | 27 (23.7%) |
|
| 7 (14.3%) | 21 (22.6%) | 1.81 (0.71–4.65) | 0.2 | ||
| Overdominant | AA/GG | 86 (53.8%) | 67 (58.8%) | 1.00 | 25 (51%) | 53 (57%) | 1.00 | |||
| AG | 74 (46.2%) | 47 (41.2%) | 0.81 (0.49–1.32) | 0.39 | 24 (49%) | 40 (43%) | 0.77 (0.38–1.54) | 0.45 | ||
| Codominant | CC | 76 (47.8%) | 63 (58.3%) | 1.00 | 25 (51%) | 65 (71.4%) | 1.00 | |||
| CT | 58 (36.5%) | 32 (29.6%) | 0.67 (0.39–1.15) | 0.23 | 21 (42.9%) | 13 (14.3%) |
|
| ||
| TT | 25 (15.7%) | 13 (12%) | 0.62 (0.29–1.32) | 3 (6.1%) | 13 (14.3%) | 1.70 (0.44–6.51) | ||||
| Dominant | CC | 76 (47.8%) | 63 (58.3%) | 1.00 | 25 (51%) | 65 (71.4%) | 1.00 | |||
| CT/TT | 83 (52.2%) | 45 (41.7%) | 0.65 (0.40–1.07) | 0.09 | 24 (49%) | 26 (28.6%) |
|
| ||
| Recessive | CC/CT | 134 (84.3%) | 95 (88%) | 1.00 | 46 (93.9%) | 78 (85.7%) | 1.00 | |||
| TT | 25 (15.7%) | 13 (12%) | 0.73 (0.35–1.49) | 0.38 | 3 (6.1%) | 13 (14.3%) | 2.61 (0.70–9.71) | 0.12 | ||
| Overdominant | CC/TT | 101 (63.5%) | 76 (70.4%) | 1.00 | 28 (57.1%) | 78 (85.7%) | 1.00 | |||
| CT | 58 (36.5%) | 32 (29.6%) | 0.74 (0.44–1.24) | 0.25 | 21 (42.9%) | 13 (14.3%) |
|
| ||
Distribution of ULK1 and PIK3CA polymorphisms in population of different sex and its association with the risk of MPA.
| SNP ID | Model | Geno- | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control | Case | OR (95% CI) | Control | Case | OR (95% CI) | |||||
| Codominant | AA | 31 (37.8%) | 23 (29.1%) | 1.00 | 61 (48%) | 44 (34.1%) | 1.00 | |||
| GA | 38 (46.3%) | 46 (58.2%) | 1.63 (0.82–3.26) | 0.32 | 47 (37%) | 67 (51.9%) | 1.86 (1.08–3.20) | 0.08 | ||
| GG | 13 (15.8%) | 10 (12.7%) | 1.03 (0.38–2.77) | 19 (15%) | 18 (13.9%) | 1.28 (0.60–2.73) | ||||
| Dominant | AA | 31 (37.8%) | 23 (29.1%) | 1.00 | 61 (48%) | 44 (34.1%) | 1.00 | |||
| GA/GG | 51 (62.2%) | 56 (70.9%) | 1.47 (0.76–2.86) | 0.25 | 66 (52%) | 85 (65.9%) |
|
| ||
| Recessive | AA/GA | 69 (84.2%) | 69 (87.3%) | 1.00 | 108 (85%) | 111 (86%) | 1.00 | |||
| GG | 13 (15.8%) | 10 (12.7%) | 0.76 (0.31–1.87) | 0.56 | 19 (15%) | 18 (13.9%) | 0.93 (0.46–1.88) | 0.84 | ||
| Overdominant | AA/GG | 44 (53.7%) | 33 (41.8%) | 1.00 | 80 (63%) | 62 (48.1%) | 1.00 | |||
| GA | 38 (46.3%) | 46 (58.2%) | 1.61 (0.86–3.02) | 0.13 | 47 (37%) | 67 (51.9%) |
|
| ||
| Codominant | AA | 29 (35.4%) | 28 (35.4%) | 1.00 | 52 (40.9%) | 45 (34.9%) | 1.00 | |||
| AG | 43 (52.4%) | 36 (45.6%) | 0.89 (0.45–1.76) | 0.5 | 55 (43.3%) | 51 (39.5%) | 1.04 (0.60–1.82) | 0.14 | ||
| GG | 10 (12.2%) | 15 (19%) | 1.49 (0.57–3.90) | 20 (15.8%) | 33 (25.6%) | 1.90 (0.95–3.78) | ||||
| Dominant | AA | 29 (35.4%) | 28 (35.4%) | 1.00 | 52 (40.9%) | 45 (34.9%) | 1.00 | |||
| AG/GG | 53 (64.6%) | 51 (64.6%) | 1.00 (0.52–1.92) | 0.86 | 75 (59.1%) | 84 (65.1%) | 1.27 (0.76–2.12) | 0.36 | ||
| Recessive | AA/AG | 72 (87.8%) | 64 (81%) | 1.00 | 107 (84.2%) | 96 (74.4%) | 1.00 | |||
| GG | 10 (12.2%) | 15 (19%) | 1.60 (0.67–3.84) | 0.25 | 20 (15.8%) | 33 (25.6%) |
|
| ||
| Overdominant | AA/GG | 39 (47.6%) | 43 (54.4%) | 1.00 | 72 (56.7%) | 78 (60.5%) | 1.00 | |||
| AG | 43 (52.4%) | 36 (45.6%) | 0.79 (0.42–1.47) | 0.51 | 55 (43.3%) | 51 (39.5%) | 0.83 (0.50–1.38) | 0.48 | ||
| Codominant | CC | 39 (47.6%) | 51 (66.2%) | 1.00 | 62 (49.2%) | 78 (63.4%) | 1.00 | |||
| CT | 29 (35.4%) | 15 (19.5%) |
|
| 50 (39.7%) | 30 (24.4%) |
|
| ||
| TT | 14 (17.1%) | 11 (14.3%) | 0.60 (0.25–1.47) | 14 (11.1%) | 15 (12.2%) | 0.93 (0.41–2.11) | ||||
| Dominant | CC | 39 (47.6%) | 51 (66.2%) | 1.00 | 62 (49.2%) | 78 (63.4%) | 1.00 | |||
| CT/TT | 43 (52.4%) | 26 (33.8%) |
|
| 64 (50.8%) | 45 (36.6%) |
|
| ||
| Recessive | CC/CT | 68 (82.9%) | 66 (85.7%) | 1.00 | 112 (88.9%) | 108 (87.8%) | 1.00 | |||
| TT | 14 (17.1%) | 11 (14.3%) | 0.81 (0.34–1.91) | 0.63 | 14 (11.1%) | 15 (12.2%) | 1.21 (0.55–2.66) | 0.64 | ||
| Overdominant | CC/TT | 53 (64.6%) | 62 (80.5%) | 1.00 | 76 (60.3%) | 93 (75.6%) | 1.00 | |||
| CT | 29 (35.4%) | 15 (19.5%) |
|
| 50 (39.7%) | 30 (24.4%) |
|
| ||
| GA | 59 (38.6%) | 68 (52.3%) |
|
| 26 (46.4%) | 42 (5%) | 1.42 (0.69–2.89) | 0.34 | ||
Distribution of ULK1 and PIK3CA polymorphisms in population of different ethnicity and its association with the risk of MPA.
|
|
|
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control | Case | OR (95% CI) | Control | Case | OR (95% CI) | |||||
| Codominant | AA | 73 (47.7%) | 43 (33.1%) | 1.00 | 19 (33.9%) | 24 (32%) | 1.00 | |||
| GA | 59 (38.6%) | 68 (52.3%) | 1.88 (1.12–3.17) | 0.054 | 26 (46.4%) | 42 (56%) | 1.24 (0.56–2.76) | 0.48 | ||
| GG | 21 (13.7%) | 19 (14.6%) | 1.48 (0.71–3.07) | 11 (19.6%) | 9 (12%) | 0.67 (0.23–1.98) | ||||
| Dominant | AA | 73 (47.7%) | 43 (33.1%) | 1.00 | 19 (33.9%) | 24 (32%) | 1.00 | |||
| GA/GG | 80 (52.3%) | 87 (66.9%) |
|
| 37 (66.1%) | 51 (68%) | 1.07 (0.50–2.28) | 0.86 | ||
| Recessive | AA/GA | 132 (86.3%) | 111 (85.4%) | 1.00 | 45 (80.4%) | 66 (88%) | 1.00 | |||
| G/G | 21 (13.7%) | 19 (14.6%) | 1.06 (0.54–2.07) | 0.87 | 11 (19.6%) | 9 (12%) | 0.58 (0.22–1.55) | 0.28 | ||
| Overdominant | AA/GG | 94 (61.4%) | 62 (47.7%) | 1.00 | 30 (53.6%) | 33 (44%) | 1.00 | |||
| GA | 59 (38.6%) | 68 (52.3%) |
|
| 26 (46.4%) | 42 (5%) | 1.42 (0.69–2.89) | 0.34 | ||
| Codominant | AA | 60 (39.2%) | 47 (36.1%) | 1.00 | 21 (37.5%) | 25 (33.3%) | 1.00 | |||
| AG | 72 (47.1%) | 54 (41.5%) | 0.94 (0.56–1.59) | 0.18 | 26 (46.4%) | 32 (42.7%) | 1.07 (0.49–2.37) | 0.62 | ||
| GG | 21 (13.7%) | 25 (22.3%) | 1.74 (0.88–3.45) | 9 (16.1%) | 18 (24%) | 1.61 (0.59–4.41) | ||||
| Dominant | AA | 60 (39.2%) | 47 (36.1%) | 1.00 | 21 (37.5%) | 25 (33.3%) | 1.00 | |||
| AG/GG | 93 (60.8%) | 83 (63.9%) | 1.12 (0.69–1.83) | 0.64 | 35 (62.5%) | 50 (66.7%) | 1.22 (0.58–2.54) | 0.6 | ||
| Recessive | AA/AG | 132 (86.3%) | 104 (77%) | 1.00 | 47 (83.9%) | 57 (76%) | 1.00 | |||
| GG | 21 (13.7%) | 31 (23%) | 1.80 (0.96–3.35) | 0.064 | 9 (16.1%) | 18 (24%) | 1.55 (0.62–3.86) | 0.34 | ||
| Overdominant | AA/GG | 81 (52.9%) | 79 (58.5%) | 1.00 | 30 (53.6%) | 43 (57.3%) | 1.00 | |||
| AG | 72 (47.1%) | 56 (41.5%) | 0.79 (0.49–1.27) | 0.33 | 26 (46.4%) | 32 (42.7%) | 0.91 (0.44–1.87) | 0.8 | ||
| Codominant | CC | 76 (49.7%) | 86 (68.2%) | 1.00 | 25 (45.5%) | 40 (56.3%) | 1.00 | |||
| CT | 59 (38.6%) | 27 (21.4%) |
|
| 20 (36.4%) | 18 (25.4%) | 0.59 (0.26–1.36) | 0.47 | ||
| TT | 18 (11.8%) | 13 (10.3%) | 0.68 (0.31–1.49) | 10 (18.2%) | 13 (18.3%) | 0.81 (0.30–2.18) | ||||
| Dominant | CC | 76 (49.7%) | 86 (68.2%) | 1.00 | 25 (45.5%) | 40 (56.3%) | 1.00 | |||
| CT/TT | 77 (50.3%) | 40 (31.8%) |
|
| 30 (54.5%) | 31 (43.7%) | 0.67 (0.32–1.37) | 0.27 | ||
| Recessive | CC/CT | 135 (88.2%) | 113 (89.7%) | 1.00 | 45 (81.8%) | 58 (81.7%) | 1.00 | |||
| TT | 18 (11.8%) | 13 (10.3%) | 0.91 (0.43–1.97) | 0.82 | 10 (18.2%) | 13 (18.3%) | 0.97 (0.38–2.51) | 0.96 | ||
| Overdominant | CC/TT | 94 (61.4%) | 99 (78.6%) | 1.00 | 35 (63.6%) | 53 (74.7%) | 1.00 | |||
| CT | 59 (38.6%) | 27 (21.4%) |
|
| 20 (36.4%) | 18 (25.4%) | 0.63 (0.28–1.38) | 0.24 | ||
Figure 2Distribution of high-risk and low risk genotypes in the best two-locus model.
Dark gray and light gray boxed presented the high- and low- risk factor combinations, respectively. Left bars within each box represented case with positive score, right bars represented negative score. The higher the positive score, the greater the combination risk. GA in rs4964879 and CC in rs1607237 showed the most risk combinations.